These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 19361233)

  • 1. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand.
    Kularatne SA; Wang K; Santhapuram HK; Low PS
    Mol Pharm; 2009; 6(3):780-9. PubMed ID: 19361233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents.
    Kularatne SA; Zhou Z; Yang J; Post CB; Low PS
    Mol Pharm; 2009; 6(3):790-800. PubMed ID: 19361232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
    J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
    Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
    Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and Biological Evaluation of [
    Xiao D; Duan X; Gan Q; Zhang X; Zhang J
    Molecules; 2020 Nov; 25(23):. PubMed ID: 33256058
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Xu X; Zhang J; Hu S; He S; Bao X; Ma G; Luo J; Cheng J; Zhang Y
    Nucl Med Biol; 2017 May; 48():69-75. PubMed ID: 28273495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
    Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
    J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer.
    Kratochwil C; Giesel FL; Leotta K; Eder M; Hoppe-Tich T; Youssoufian H; Kopka K; Babich JW; Haberkorn U
    J Nucl Med; 2015 Feb; 56(2):293-8. PubMed ID: 25613537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
    Hillier SM; Maresca KP; Femia FJ; Marquis JC; Foss CA; Nguyen N; Zimmerman CN; Barrett JA; Eckelman WC; Pomper MG; Joyal JL; Babich JW
    Cancer Res; 2009 Sep; 69(17):6932-40. PubMed ID: 19706750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
    Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
    J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
    Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
    J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.
    Lapi SE; Wahnishe H; Pham D; Wu LY; Nedrow-Byers JR; Liu T; Vejdani K; VanBrocklin HF; Berkman CE; Jones EF
    J Nucl Med; 2009 Dec; 50(12):2042-8. PubMed ID: 19910433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.
    Vallabhajosula S; Nikolopoulou A; Babich JW; Osborne JR; Tagawa ST; Lipai I; Solnes L; Maresca KP; Armor T; Joyal JL; Crummet R; Stubbs JB; Goldsmith SJ
    J Nucl Med; 2014 Nov; 55(11):1791-8. PubMed ID: 25342385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
    Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE
    Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.
    Evazalipour M; D'Huyvetter M; Tehrani BS; Abolhassani M; Omidfar K; Abdoli S; Arezumand R; Morovvati H; Lahoutte T; Muyldermans S; Devoogdt N
    Contrast Media Mol Imaging; 2014; 9(3):211-20. PubMed ID: 24700748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen.
    Mosayebnia M; Hajimahdi Z; Beiki D; Rezaeianpour M; Hajiramezanali M; Geramifar P; Sabzevari O; Amini M; Hatamabadi D; Shahhosseini S
    Bioorg Chem; 2020 Jun; 99():103743. PubMed ID: 32217372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery of Siape1 and Melatonin by
    Liu Y; Hao L; Dong Y; Dong BZ; Wang XL; Liu X; Hu ZX; Fang GC; Wang GY; Qin JX; Shi ZD; Pang K
    Recent Pat Anticancer Drug Discov; 2024; 19(4):503-515. PubMed ID: 39044710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of PSMA-specific peptide ligands for targeted drug delivery.
    Jin W; Qin B; Chen Z; Liu H; Barve A; Cheng K
    Int J Pharm; 2016 Nov; 513(1-2):138-147. PubMed ID: 27582001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
    Ganguly T; Dannoon S; Hopkins MR; Murphy S; Cahaya H; Blecha JE; Jivan S; Drake CR; Barinka C; Jones EF; VanBrocklin HF; Berkman CE
    Nucl Med Biol; 2015 Oct; 42(10):780-7. PubMed ID: 26169882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.